Spots Global Cancer Trial Database for gemox
Every month we try and update this database with for gemox cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | NCT05251662 | Intrahepatic Ch... | Sintilimab IBI305 GEMOX | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma | NCT05430698 | Perihilar Chola... | PD-1antibody pl... | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Gemox as First and Second Line Therapy in Unknown Primary Cancer | NCT00353145 | Unknown Primary... | Gemcitabine (Ge... Oxaliplatin Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL | NCT02624492 | Lymphoma, Large... | BI 836826 GemOx Rituximab GemOx | 18 Years - | Boehringer Ingelheim | |
| Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | NCT05251662 | Intrahepatic Ch... | Sintilimab IBI305 GEMOX | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma | NCT05430698 | Perihilar Chola... | PD-1antibody pl... | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer | NCT01487720 | Prostate Cancer | GEMOX | 18 Years - | Asan Medical Center | |
| Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma | NCT05381506 | DLBCL | Orelabrutinib a... | 18 Years - | Sun Yat-sen University | |
| Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma | NCT02548195 | Cholangiocarcin... | oxaliplatin and... capecitabine | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC | NCT03092895 | Advanced Primar... Advanced Biliar... | SHR-1210 Apatinib FOLFOX4 GEMOX | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer | NCT00361231 | Biliary Tract C... Gallbladder Ade... | Bevacizumab Gemcitabine Oxaliplatin | 18 Years - | Massachusetts General Hospital | |
| Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) | NCT06320301 | Biliary Tract C... Gemox Chemother... | Adebrelimab + G... | - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | NCT02836847 | Cholangiocarcin... Gallbladder Can... | biological test GEMOX Cetuximab Trastuzumab Gefitinib Lapatinib Everolimus Sorafenib Crizotinib | 18 Years - 80 Years | Shanghai Jiao Tong University School of Medicine | |
| Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) | NCT06320301 | Biliary Tract C... Gemox Chemother... | Adebrelimab + G... | - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma | NCT01487915 | Advanced Urothe... | GCb GemOx | 18 Years - | Asan Medical Center | |
| To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL | NCT02624492 | Lymphoma, Large... | BI 836826 GemOx Rituximab GemOx | 18 Years - | Boehringer Ingelheim | |
| Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer | NCT02386397 | Digestive Cance... | Regorafenib GEMOX | 18 Years - 75 Years | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma | NCT02548195 | Cholangiocarcin... | oxaliplatin and... capecitabine | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma | NCT05381506 | DLBCL | Orelabrutinib a... | 18 Years - | Sun Yat-sen University | |
| Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer | NCT05156788 | Biliary Tract C... PD-1 Antibody Gemox Lenvatinib | PD-1+Lenvatinib... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) | NCT06320301 | Biliary Tract C... Gemox Chemother... | Adebrelimab + G... | - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma | NCT02534337 | Hepatocellular ... | GEMOX FOLFOX4 | 18 Years - 75 Years | Guangxi Medical University | |
| A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC | NCT03092895 | Advanced Primar... Advanced Biliar... | SHR-1210 Apatinib FOLFOX4 GEMOX | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
